Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 174-177

  Tiribelli, Mario ^a   Sperotto, Alessandra ^a   Candoni, Anna ^a   Simeone, Erica ^a   Buttignol, Silvia ^a   Fanin, Renato ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

DLI; Nilotinib; Philadelphia positive ALL; Post transplant relapse

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; IFOSFAMIDE; IMATINIB; METHOTREXATE; MITOXANTRONE; NILOTINIB; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASE REPORT; CLINICAL FEATURE; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; ERYTHEMA; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 55049088837     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.031     Document Type: Article

References (18)

1. Ottmann O.G., and Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program (2005) 118-122
2. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86 (1995) 2041-2050
3. Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancies after allogeneic bone marrow transplantation. J Clin Oncol 15 (1997) 433-444
4. Collins Jr. R.H., Goldstein S., Giralt S., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 26 (2000) 511-516
5. Shiobara S., Nakao S., Ueda M., et al. Donor leukocyte infusion for Japanese patients with relapsed luekemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 26 (2000) 769-774
6. Kolb H.J., Schmid C., Barrett A.J., et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
7. Choi S.J., Lee J.H., Lee J.H., et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 36 (2005) 163-169
8. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
9. Ottmann O.G., Druker B.J., Sawyers C.L., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemia. Blood 100 (2002) 1965-1971
10. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141 [Erratum in: Cancer Cell 2005;7:399]
11. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
12. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia-positive ALL. N Engl J Med 354 (2006) 2542-2551
13. Hoelzer D., Ludwig W.D., Thiel E., et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87 (1996) 495-508
14. Wassmann B., Pfeifer H., and Stadler M. Early molecular response to posttransplantation imatinb determines outcome in MDR+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 106 (2005) 458-463
15. Carpenter P.A., Snyder D.S., Flowers M.E.D., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109 (2007) 2791-2793
16. Blair A., Goulden N.J., Libri N.A., et al. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev 19 (2005) 289-300
17. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients. Clin Cancer Res 12 (2006) 7374-7379
18. Pfeifer H., Wassmann B., Pavlova A., et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110 (2007) 727-734